Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
BMJ Publishing Group
2024-02-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/1/e001629corr1.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849720511835144192 |
|---|---|
| collection | DOAJ |
| format | Article |
| id | doaj-art-500d31e71d8f4d37a33d35763adf587e |
| institution | DOAJ |
| issn | 2056-5933 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-500d31e71d8f4d37a33d35763adf587e2025-08-20T03:11:54ZengBMJ Publishing GroupRMD Open2056-59332024-02-0110110.1136/rmdopen-2021-001629corr1Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south koreahttps://rmdopen.bmj.com/content/10/1/e001629corr1.full |
| spellingShingle | Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea RMD Open |
| title | Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea |
| title_full | Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea |
| title_fullStr | Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea |
| title_full_unstemmed | Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea |
| title_short | Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea |
| title_sort | correction long term open label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea |
| url | https://rmdopen.bmj.com/content/10/1/e001629corr1.full |